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In this section, initially the drugs for bronchial asthma and Chronic Obstructive Pulmonary 
Disease (COPD) are considered.  This is followed by a discussion of expectorants, 
mucolytics, drugs for cough and oxygen, and then of the drugs for rhinitis and rhinorrhea.  
Finally, drugs for smoking cessation are considered as smoking cessation would prevent 
much respiratory illness. 
 
 
17.1. Drugs for bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD) 
 
 17.1.1 Introduction to asthma 
The symptoms of bronchial asthma are coughing, wheezing, shortness of breath, and chest 
tightness. Asthma remains a significant health problem in Australia, with prevalence and 
death rates that are high by international standards despite declines Asthma affects more than 
1 in 10 Australians - equivalent to over 2 million people and in 2008, 447 Australians died 
from asthma. The reason for the high prevalence of asthma in Australia is not known  
There are more paediatric hospital admissions for asthma than for any other cause. 
 
What is bronchial asthma?  Bronchial asthma is an inflammatory disease with increased 
airway thickness, increased number of inflammatory cells, inflammation, bronchial hyper-
reactivity and bronchoconstriction.  Bronchial hyper-reactivity is cough and wheeze in 
response to stimuli (such as strong odours, cold air, pollutants and histamine) that would not 
provoke such a response in normal subjects.  Some asthma is allergic.  In severe asthma, 50-
80% of this has an allergic component.  In allergic asthma immunoglobulin E (IgE) plays an 
important part in the inflammatory cascade, and a logical way to treat allergic asthma is to 
prevent the effects of IgE. 
 
The increased number of inflammatory cells in bronchial asthma occurs under basal 
conditions and with the presence of allergen.  As there are many mediators involved in 
inflammatory processes, targeting one mediator is not always successful.  For instance, 
histamine is a mediator of inflammation, but histamine acting at histamine H1-receptors only 
has a minor role in bronchial asthma.  Consequently, the anti-histamines (histamine H1-
receptor antagonists) are ineffective in the treatment of asthma.   
 
Leukotrienes, cytokines and other mediators have a major role in bronchial asthma.  Drugs 
that target only one of the inflammatory mediators are not fully effective in inflammation.  
Thus, drugs that target more than one inflammatory mediator have a major role in 
treating the inflammation of asthma.  Asthma is usually a short-term impairment in 
respiration, whereas Chronic Obstructive Pulmonary Disease (COPD) is long-term 
impairment in respiration, and can be permanent. 
 
 17.1.2 Introduction to COPD 
COPD is associated with chronic bronchitis and in the later stages, emphysema.  In chronic 
bronchitis there is excessive production of sputum, breathlessness and cough.  In chronic 
bronchitis, there is alveolar hypoventilation, hypercapnia and hypoxia.  There is also an 
airway narrowing and mucus plug, and the mucus plugs provide an environment suitable for 
secondary infection.   
 
In emphysema, there is a permanent, destructive enlargement of air spaces distal to the 
terminal bronchiole.  There is progressive airflow limitation largely due to enzymatic 
destruction of elastin fibres in the lung parenchyma. 
 
COPD occurs mainly in smokers, develops over years with a progressive decline in lung 
function.  COPD is the fourth leading cause of death in the US, and the leading cause of 
preventable death.  Smoking cessation is the only intervention that has been shown to slow 
decline in pulmonary function, and the drug interventions to promote smoking cessation are 
discussed in Chapter 35.  Unfortunately, only 20-40% of COPD patients quit smoking. 
 
 17.1.3 Drug delivery by inhalation 
Unfortunately, with inhalation, not all the drug goes to the lungs.  For instance, it has been 
shown that if an aerosol is used to deliver particles of 1-5 μm, after inhalation, only 10% of 
the drug ends up in the lungs to have its beneficial effect.  The rest of the drug, 90% is 
swallowed, and has the potential to be absorbed, circulated and to cause adverse effects.  This 
means that when drugs are designed for inhalation, it is still necessary to prevent systemic 
effects, if possible.  One approach is to limit the absorption from the gastrointestinal tract.  
Another approach is to have a drug that is metabolised in the gut or undergoes extensive first 
pass liver metabolism.  Both of these approaches are used with glucocorticoids, where it 
important to limit access to the circulation, and systemic adverse effects. 
 
 17.1.4 Drugs to treat 
17.1.4.1 β2-adrenoceptor agonists 
Adrenaline is a hormone released from adrenal medulla that has widespread effects including 
stimulating bronchial 2-adrenoceptors to induce bronchodilation via cell-signaling involving 
adenylate cyclase.  Salbutamol is a short-acting and salmeterol is a long-acting selective 2-
adrenoceptors agonist.  Both salbutamol and salmeterol stimulate 2-adrenoceptors to cause 
relaxation of bronchial smooth muscle, and both are used clinically as bronchodilators in 
asthma, but they are used in different ways. 
 
Salbutamol is a short acting selective 2-adrenoceptor agonist, which is inhaled for the 
symptomatic relief of an asthma attack (dyspnea - shortness of breath) on an as needed basis.  
Thus, it is only used when an attack of asthma occurs, and salbutamol is quick acting.  There 
is an onset of action within a few minutes, and the bronchodilation continues for 3-4 hours. In 
the emergency treatment of asthma, it may be necessary to use doses of salbutamol that are 
higher than in the normal salbutamol inhaler.  Thus, in the emergency treatment of asthma, 
salbutamol can be delivered in a nebuliser.  Nebulisers produce fine droplets in the air 
(aerosol), and are used to deliver large doses of drugs (in this case, salbutamol) in an 
emergency.  
  
When the symptoms of asthma become persistent, subjects are not being managed well with 
salbutamol alone, and the treatment has to be re-evaluated and prophylactic (preventative) 
treatment may be indicated.  Salmeterol is a long lasting selective 2-adrenoceptor agonist 
(LABA).  It is used as a chronic regular inhalation for a prophylactic effect in asthma i.e. 
ongoing bronchodilation to prevent an asthma attack.  Salmeterol has a slow onset of action, 
which makes it unsuitable for use in acute attacks of asthma.  Salmeterol has a duration of 
action of greater than 12 hours, and is usually used as an inhalation, either once or twice a 
day.  It has been shown that the chronic use of salmeterol improves lung function, decreases 
asthma symptoms, decreases nocturnal asthma and also decreases the use of short acting 2- 
adrenoceptor agonists.  Thus, asthmatics continue to carry their salbutamol inhalers for use in 
asthma attacks, but when they are taking salmeterol, there are less asthma attacks, and less 
use of short acting 2- adrenoceptor agonists.    
 
However, long term use of salmeterol is associated with increased risk of asthma 
exacerbations and death.  Thus, it is not introduced into the treatment of asthma, unless it has 
been shown that a maximum dose of glucocorticoid is ineffective alone.  If the maximum 
dose of glucocorticoid alone does not prevent exacerbation, salmeterol may be introduced, as 
in this situation the benefits of salmeterol outweighs the risks of salmeterol.  Salmeterol is 
used in combination with a glucocorticoid in a single inhaler, as use of a single inhaler 
improves adherence to the asthma medicine, and the control of the asthma. 
 
As both salbutamol and salmeterol are β2-adrenoceptor selective, not specific, the side effects 
of high doses included 1-adrenoceptor mediated increase in heart rate, sometimes 
leading to cardiac arrhythmias.  2-Adrenoceptor agonists are used in the treatment of 
COPD, but their beneficial effect is marginal. 
 
  17.1.4.2 Muscarinic receptor antagonists 
Ipratropium bromide (discussed previously in Chapter 14.4) and tiotropium are muscarinic 
receptor antagonists used in the treatment of asthma.  The main advantage ipratropium has 
over other anti-muscarinics (e.g. atropine) is limited absorption and, therefore, limited 
systemic side effects.  The mechanism of action of ipratropium and of tiotropium is as non-
selective muscarinic receptor antagonists, which prevents acetylcholine from stimulating 
muscarinic receptors and causing bronchoconstriction.  Effectively, the action observed with 
ipratropium/tiotropium is relaxation of smooth muscle. Tiotropium has a longer half-life than 
ipratropium and only requires once a day dosing. Ipratropium and tiotropium are occasionally 
used as bronchodilators in asthma.  They are sometimes used in combination with a β2-
adrenoceptor agonist to give an additive effect.  The muscarinic receptor antagonists can also 
be used with glucocorticoids as alternatives to β2-adrenoceptor agonists 
 
 17.1.4.3 Leukotriene Receptor antagonists 
Montelukast is a leukotriene receptor antagonist that is used in the prevention of asthma.  




Theophylline was discussed in eChapter 3.  Theophylline is a phosphodiesterase inhibitor.  
As a result of inhibiting phosphodiesterase, theophylline causes an increase in the levels of 
cAMP in the bronchial smooth muscle.  The levels of cAMP determine the degree of 
bronchodilation, and when the levels are increased, there is an increased relaxation of smooth 
muscle.  By inhibiting phosphodiesterase, theophylline inhibits the breakdown of cAMP, to 
cause an increased bronchodilation Theophylline is used clinically as a bronchodilator, 
mainly in the emergency treatment of asthma, especially when asthma is continuing despite 
the use of a β2-adrenoceptor agonist. 
 
17.1.4.5 Oxygen for COPD 
In severe COPD, there is persistent hypoxemia (low levels of circulating oxygen).  The 
obvious way to overcome this is to give oxygen at high levels than in atmosphere. Thus, in 
severe COPD, there is home use of oxygen for up to 18 hours a day, and this includes sleep 
time.  The oxygen is usually administered by a nasal cannula i.e. cannula up the nose. Low 
concentrations of oxygen are required, as subjects with COPD have high concentrations of 
carbon dioxide, and if these are further increased they may develop hypercapnia (carbon 
dioxide poisoning).  
 
 17.1.5 Drugs to prevent asthma  
  1.5.1 Glucocorticoids 
The glucocorticoids have been previously discussed as drugs that have effects mediated by 
intracellular receptors (eChapter 3).  The endogenous and synthetic glucocorticoids readily 
get into the cytoplasm of all cells, but only some of the cells have receptors for the 
glucocorticoids.  When the glucocorticoid is bound to the receptor, it moves to the nucleus, 
and protein synthesis is initiated.  Some of the proteins synthesized have anti-inflammatory 
actions. 
 
There are many components to inflammation including the synthesis of prostaglandins, 
leukotrienes, cytokines, adhesion molecules and the release of histamine and leukotrienes, 
and all of these components are inhibited by the glucocorticoids.  The glucocorticoids 
commonly used in asthma include beclomethasone and budesonide.  All are inhaled.  One 
problem with inhalation is that the glucocorticoid deposited in the mouth can lead to reduced 
immunity, and candidiasis (thrush) can develop.  This can be minimised by using a spacer 
and by washing out the mouth and throat after using a glucocorticoid inhaler.  The 
glucocorticoids are prophylactic (preventative) in the treatment of asthma.  They cause an 
improvement in symptoms, so that there are less attacks of asthma, and this can be 
demonstrated by a reduced use of short-acting -adrenoceptor agonists in subjects that take 
prophylactic glucocorticoids. 
 
As drug delivery by inhalation, not only delivers drug to the lungs, but also to the 
gastrointestinal tract, the glucocorticoids for asthma have been designed to limit systemic 
effects.  Thus, beclomethasone crosses membranes poorly, which means it has limited 
absorption from gastro-intestinal tract, and limited systemic side effects budesonide is well 
absorbed from the gastrointestinal tract, but have extensive first pass liver metabolism, which 
limits access to the circulation and decreases the risk of systemic side effects.   
 
When there are acute exacerbations of asthma, it may be necessary to use systemic 
prednisone to overcome asthma.  Prednisone is more potent than beclomethasone or 
budesonide as an anti-inflammatory.  However, the systemic use of prednisone must be short-
term use to prevent systemic adverse effects.   
 
Glucocorticoids are also used in the treatment of COPD, where they give only a little 
benefit.  Nevertheless they are used as there are no medicines that give a major benefit in 
COPD. 
 
In addition to being anti-inflammatory agents, the endogenous glucocorticoids have lots of 
other effects in the body, and these are mimicked or exaggerated by the more potent 
glucocorticoids used as medicines.  Administered glucocorticoids mimic the endogenous 
glucocorticoids to turn off the hypothalamus-pituitary-adrenal axis.  With the long term 
systemic use (Table 17.1), the administration of systemic glucocorticoids causes suppression 
of the axis, which is slow to reverse.  Thus, after long term systemic use, glucocorticoids 
have to be withdrawn slowly or there will be major problems due to the lack of the 
endogenous compounds produced by the axis.  This means that even if there are severe 
detrimental effects, which there can be with the glucocorticoids, they cannot be withdrawn 
immediately.  With the inhalation of beclomethasone or budesonide, or the short-term use of 
oral prednisone, there is no suppression of the hypothalamus-pituitary-adrenal axis.  
However, this can occur if high doses of the inhaled glucocorticoids are used. 
 
Most people with asthma take a glucocorticoid to prevent the inflammatory component of 
asthma and a long acting β-adrenoceptor agonist (LABA).  For ease of use, salmeterol is 
often used in combination with a glucocorticoid in a single inhaler.  Using one inhaler for 
both the glucocorticoid and LABA, instead of two inhalers, increases the adherence to the 
medication, and reduces the exacerbations of asthma. 
 
 
Table 17.1 Adverse effects with glucocorticoids 
 
With long term systemic used of glucocorticoids, growth retardation in children may 
occur, but this has not been reported with inhalation of glucocorticoids.  The glucocorticoids 
promote bone resorption, and this leads to osteoporosis (thinning of the bone) and 
osteonecrosis (breakdown of bone).  Osteoporosis is observed with the long term systemic 
used of glucocorticoids, but is relative modest with inhalation or short term use of the 
glucocorticoids.  The glucocorticoids have major effects on both carbohydrate and lipid 
metabolism leading to hyperglycaemia and fat redistribution.  This is a major problem with 
the systemic long term use of glucocorticoids but only a minor problem with inhaled or short 
term use of oral glucocorticoids.  Long term glucocorticoid use is associated with cataracts, 
but this is unproven with inhaled or short term use of oral glucocorticoids.   Systemically 
administered glucocorticoids cause skin thinning, but this is only observed with long term 
use of high doses of inhaled steroids. 
 
17.1.5.2 Cromolyn sodium  
The other drugs used to prevent asthma are the mast cell stabilisers including cromolyn 
sodium. The exact mechanism of action of cromolyn sodium is unknown, but it is known that 
it leads to an inhibition of mediator release from mast cells, and these mediators include the 
bronchoconstrictors histamine and leukotrienes.  Cromolyn sodium is taken by inhalation.  
As it is poorly absorbed from gastrointestinal tract, side effects are rare with cromolyn 
sodium.  Cromolyn sodium is used to prevent an asthma attack, but is not useful in an asthma 
attack, when the mediators have been already been released.  With regular use, cromolyn 
sodium can prevent asthma due to antigenic or exercise challenge, and can decrease bronchial 
hyper-reactivity.   
 
17.1.6 Combination treatment to treat and prevent asthma 
Formoterol is a rapidly acting selective β2-adrenoceptor, which is used in combination with 
the glucocorticoid budesonide for the treatment and prevention of asthma.  Formoterol causes 
a rapid bronchodilation to relieve the symptoms of asthma, whereas budesonide reduces the 
inflammation. 
 
17.1.7 Drug for allergic asthma – omalizumab 
Moderate-to-severe allergic asthma is treated with inhaled glucocorticoids.  If this does not 
control the asthma, and there is an allergic component, immunotherapy may be tried.  
Omalizumab is a monoclonal antibody to immunoglobulin E (IgE).  Omalizumab combines 
with IgE to prevent its actions.  Thus, omalizumab prevent IgE from promoting mast cell 
degranulation (release of histamine, leukotrienes etc).  This, in turn, reduces the immune 
response to the allergen to decrease the symptoms of asthma.  Omalizumab is not active after 
oral administration, and is administered subcutanously.  
 
17.1.7 Emergency treatment of asthma 
When subjects with asthma are taken to the emergency department of the local hospital, the 
initial treatment is usually high dose salbutamol delivered by nebulizer.  If this does not give 
enough bronchodilation, theophylline may be administered to increase the bronchodilation.  
In severe exacerbations of asthma, intravenous glucocorticoids are used, and it is usually the 
potent glucocorticoid prednisone. 
 
In the ambulance, in severe asthma high dose salbutamol may delivered by nebulizer or, if 
that is not possible, intravenously.  In severe asthma, intravenous glucocorticoid may be 
given by the paramedic.  The glucocorticoid used for this is a relatively weak glucocorticoid 
– hydrocortisone.  
 
 
17.2. Expectorants, mucolytics, cough, oxygen and entonox 
 
 17.2.1 Introduction to expectorants and mucolytics 
Expectorants remove sputum while mucolytics thin mucus.  Expectorants and mucolytics 
are used in the treatment of bronchitis associated with smoking/COPD.  Expectorants and 
mucolytics are also used in the treatment of cystic fibrosis.   
 
Cystic fibrosis is a genetic disorder that affects airways and ducts in lungs, pancreas and 
sweat glands.  In cystic fibrosis, thick and viscous secretions are produced in ducted organs 
(lungs, pancreas and sweat glands).  With these increased secretions, there is an increased 
risk of respiratory infection.  The frequent and persistent lung infections associated with 
cystic fibrosis leads to irreversible lung damage (bronchiectasis). 
 
 17.2.2 Expectorants 
Expectorants aid in removal of sputum from the bronchial passages.  The most common used 
expectorant is water, which is taken as steam from hot water in a basin or in a nebuliser.  The 
medicine used most commonly to remove sputum is the muscarinic receptor antagonist 
ipratropium bromide, which is administered by inhalation.  Both of these agents, water and 
ipratropium bromide act by thinning secretions and thereby keeping airways and organ ducts 
patent (open).  This is an effective way of combating opportunistic infections. 
 
 17.2.3 Mucolytics 
Mucolytics are agents that thin viscous mucus.  The most commonly used of these is 
acetylcysteine, which breaks disulphide bonds that pack the mucin molecule, and this thins 
the viscous mucus.  Acetylcysteine is administered in a nebuliser or using an intratracheal 
tube. 
 
 17.2.4 Cough 
A cough is a physiological mechanism to clear respiratory passages of foreign material and 
excessive secretions.  Thus, when something is irritating the bronchial mucosa this leads to 
bronchoconstriction, and the bronchoconstriction stretches the respiratory stretch 
receptors, which are also known as the cough receptors (Figure 17.1).  The stretch receptors 
send a message to central nervous system and there is a reflex cough to clear the substance 
causing the irritation. 
                   
 
Figure 17.1 The cough reflex (Copyright Sheila Doggrell, QUT) 
 
Thus, a cough performs a useful physiological function, and it is only when cough is chronic 
and/or unproductive that it becomes annoying and fatiguing. 
 
An anti-tussive is an agent used to relieve or prevent a cough.  For the cough associated with 
bronchial asthma, the selective 2-adrenoceptor agonists (e.g. salbutamol) are used.  
Salbutamol causes bronchodilation to reduce the stimulation of the respiratory stretch 
receptors.  Menthol vapour also reduces the sensitivity of the respiratory peripheral 
stretch/cough receptors. 
 
There are also centrally acting anti-tussive agents including codeine and dextromethorphan.  
Codeine is analgesic and anti-tussive.  Methorphan is an analog of codeine.  The L-isomer 
of methorphan is analgesic and addictive.  The D-isomer of methorphan (dextromethorphan) 
is not analgesic or addictive, but is anti-tussive.  Thus, dextromethorphan is the agent used to 
prevent cough. 
 
 17.2.5 Oxygen 
Oxygen gas can be considered as a medicine.  Under certain circumstances, oxygen gas is a 
very effective medicine.  It is used in hypoxic hypoxia e.g. airway obstruction, where lack of 
respiration is the cause of the lack of oxygen.  Oxygen gas is also used in ischemic hypoxia, 
where there is a lack of supply of oxygen and nutrients supplied by the blood vessels e.g. 
atherosclerosis and thromboembolism.  Oxygen gas can be administered either by inhalation 
with catheters up the nose, or using a mask that covers nose and mouth.  Low concentration 
are used in COPD, as the levels of carbon dioxide are high, but when the levels of carbon 




Entonox is a mixture of 50% oxygen and 50% of nitrous oxide.  It is commonly known as 
laughing gas.  Entonox is a self-administered anaesthetic in child birth.  On In(?) the 




17.3. Drugs for rhinitis and rhinorrhea 
 
 17.3.1 Introducton 
Rhinitis is the acute or chronic inflammation of the nasal mucosa causing itching and 
sneezing.  Rhinorrhea is excessive watery nasal secretions (a runny nose).  Rhinitis and 
rhinorrhea are caused by either viral infections (e.g. the common cold) or allergic reactions, 
such as seasonal allergies (e.g. hayfever) or chronic/perennial allergies (e.g. dust mites, 
animal dander).  Allergic rhinitis is suffered from by 1 in 5 people and this affects their 
quality of life, and reduces school and work performance.  Unlike in the allergic condition 
asthma, where histamine only has a minor role, histamine is a major mediator of rhinitis.  
Histamine H1-receptor antagonists counter the rhinitis. 
  
In rhinitis there is nasal vasodilation and increased blood vessel permeability (oedema) 
leading to an enlargement of nasal mucosa, which causes difficulty with inspiration of air 
(difficulty breathing through the nose).  Activation of the sympathetic nervous system causes 
vasoconstriction in the nasal mucosa, decreases blood vessel permeability, which in turn 
reduces the nasal mucosa size, and improves the ability to inspire through the nose.  Thus, 
sympathomimetics are useful in nasal rhinitis and congestion 
  
 17.3.2 Histamine and H1-receptor antagonists 
Histamine has a major role in allergic rhinitis.  In the presence of an allergen, the mast cells 
in the nasal mucosa degranulate to release histamine which actions on the histamine H1-
receptors on the endothelial cell lining of blood vessels to cause contraction of these cells, 
which increases the space between these cells (Figure 17.2).  Fluid and proteins can then 
move out of the blood vessels to form oedema.  This leads to inflammation of the nasal 
mucosa, which is partly due to the oedema. 
 
 
Figure 17.2 Histamine and allergy (Copyright Sheila Doggrell, QUT) 
 
The H1-receptor antagonist fexofenadine is used in the treatment of nasal allergy.  It is active 
after oral administration.  Fexofenadine cause suppression of the symptoms in rhinitis and 
rhinorrhea.  It is most effective at the beginning of the hayfever/pollen season when pollen 
counts are low.  When pollen counts get high, there are mediators other than histamine 
involved in the allergic reaction, and the anti-histamines are ineffective against mediators 
other than histamine.  These newer histamine H1-receptors antagonists do not get into the 
central nervous system and therefore cause little or no sedation. 
 
 17.3.3 Sympathomimetic 
The sympathomimetic most commonly used in rhinitis/rhinorrhea is ephedrine, which is also 
known as pseudoephedrine.  Ephedrine, as discussed in the Chapter on the sympathetic 
nervous system, is a mixed acting amine, which means it has both direct and indirect effects 
at adrenoceptors.  The direct action is that ephedrine is a weak agonist at - and - 
adrenoceptors.   The indirect action is that ephedrine releases noradrenaline, which in turn 
stimulates the - and - adrenoceptors.   
 
Ephedrine is active after oral administration, and after oral administration it causes an -
adrenoceptor-mediated vasoconstriction, which overcomes the nasal decongestant.  After oral 
administration, ephedrine also causes a 2-adrenoceptor-mediated bronchodilation, which is 
useful in bronchial congestion, which often occurs with nasal congestion.  In addition to 
being active after oral administration, ephedrine can be applied topically to the nasal mucosa 
in a nasal spray.  With topical administration, this limits the effects to the nose.  Topical 
administration limits adverse effects, but also reduces the beneficial bronchodilation.  After 
oral administration, the adverse effects observed with ephedrine include central nervous 
system stimulation, and sympathomimetic actions such as an increased heart rate 
(tachycardia) and an increased blood pressure. 
 
17.3.4 Muscarinic receptor antagonist 
Ipratropium bromide is the antimuscarinic agent used in the treatment of rhinorrhea.  It is 
used in the form of a nasal spray.  In the nose, ipratropium dries up the nasal secretions.  The 
highest concentrations of ipratropium are in the nose, and there is limited absorption, and a 
low incidence of adverse effects with this route of administration.  
 17.3.5 Cromolyn sodium  
In addition to taking agents such as the H1-receptor antagonists and the sympathomimetic 
ephedrine during rhinitis and rhinorrhea, there are medicines available to prevent these 
conditions.  The mast cells stabiliser cromolyn sodium is available as a nasal spray.  
Cromolyn sodium has to be taken as prophylaxis (prevention) from before the start of the 
allergy season, and then it will both reduce the symptoms and improve the quality of life in 
people with rhinitis and rhinorrhea. 
 
 17.3.6 Glucocorticoids 
The most effective preventatives for the treatment of rhinitis and rhinorrhea are the 
glucocorticoids.  The glucocorticoids beclomethasone and budesonide are available in nasal 
sprays.  With the use of these glucocorticoids in nasal sprays, there are no systemic side 
effects.  At the peak of the hayfever season, the glucocorticoids are more effective than the 
antihistamines, as histamine is not the only mediator of the allergy/inflammation. 
 
